Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
about
Opioid antagonists for alcohol dependenceTargeted opioid receptor antagonists in the treatment of alcohol use disordersNalmefene for the treatment of alcohol use disorders: recent data and clinical potential.Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.Imaging of opioid receptors in the central nervous systemPreclinical and clinical pharmacology of alcohol dependence.Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure.Emerging drugs to treat alcoholism.Nalmefene for treatment of alcohol dependence.Nalmefene: a review of its use in the treatment of alcohol dependence.The role of the opioid system in alcohol dependence.Pharmacotherapy of alcoholic liver disease in clinical practice.Dopamine and μ-opioid receptor dysregulation in the brains of binge-eating female rats - possible relevance in the psychopathology and treatment of binge-eating disorder.Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.Effects of lisdexamfetamine in a rat model of binge-eating.Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.[Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].Severe opioid withdrawal syndrome after a single dose of nalmefene.Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.Nalmefene Prevents Alcohol-Induced Neuroinflammation and Alcohol Drinking Preference in Adolescent Female Mice: Role of TLR4.Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
P2860
Q24235797-75D6F25F-7735-470C-9C48-C22AD5F64765Q28295125-62419E1E-3451-4ADA-81CE-6A90D9CD2F33Q31039835-2B06B80F-0D11-4D96-B931-C4A405E00F16Q34003725-13A572E7-01AC-41A0-8FFA-49D7D16248F3Q34180425-D639A8FF-278D-4FDA-9E39-09E6E4CF815AQ36633126-617FECF2-3E7D-413E-A217-40F02F63AC3CQ36709633-22EC60E4-B134-4E26-BA45-EE0639B17351Q36802045-F773B2B6-4927-43E1-A314-8ED6F9D2D5FCQ37209893-6E8F3182-0102-46C4-BFF9-A8EF8D43179FQ37766239-FD64298F-CCA8-4B03-80E2-69BC2A48C1BDQ37792101-0D9FBA91-E92E-4074-B925-DC31D4409CE0Q38129335-E324D18A-2CAE-4332-A56F-368B29C1924DQ38139197-BD33D3EF-B5B3-4B5B-ABC2-C1AFDB3432CFQ38681092-9703A814-FC1B-4B7C-808D-80C90A8E8A5FQ38855288-337FCB70-FF14-4F1F-B294-50C8BB59EE99Q39200931-646A565C-27D4-4F19-AF61-C30F7B4A9404Q40295381-60C3C8F8-6354-4A0F-8B95-5E372A144842Q42406039-0E1FB71E-ABD2-4E54-93F4-83E939FD1939Q43914543-7D332F63-34EA-484F-A8AB-054F7FB485BCQ44330053-116CEE1C-0707-45F1-ABF4-74F6594D9C61Q44335920-8A48BCA7-9DDB-4A26-9879-F663577F1C09Q47698059-3287F5B5-0160-4B71-AE9D-4D6314310DC5Q47767037-019E7980-2817-482F-BE01-CD204D346CF3Q51406750-81BDE088-9E79-4A0D-89F6-C832C77D967E
P2860
Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prolonged central mu-opioid re ...... and repeated nalmefene dosing.
@ast
Prolonged central mu-opioid re ...... and repeated nalmefene dosing.
@en
type
label
Prolonged central mu-opioid re ...... and repeated nalmefene dosing.
@ast
Prolonged central mu-opioid re ...... and repeated nalmefene dosing.
@en
prefLabel
Prolonged central mu-opioid re ...... and repeated nalmefene dosing.
@ast
Prolonged central mu-opioid re ...... and repeated nalmefene dosing.
@en
P2093
P2860
P50
P356
P1476
Prolonged central mu-opioid re ...... and repeated nalmefene dosing.
@en
P2093
Antero Kallio
Auni Juhakoski
Jarmo Hietala
Kimmo Ingman
Kjell Någren
Nora Hagelberg
Sakari Karhuvaara
P2860
P2888
P304
P356
10.1038/SJ.NPP.1300790
P407
P577
2005-12-01T00:00:00Z
P5875
P6179
1016493335